The Fourth People's Hospital of Nanning
8
3
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Noninvasive Diagnosis Model for High-risk Varices in Cirrhosis
Role: collaborator
PCP in Immunocompromised Population in Southern China
Role: collaborator
Simplified Treatment of Anti-retrovirus in China (C-STAR)
Role: collaborator
Dolutegravir Plus Lamivudine Simplified Therapy
Role: collaborator
Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients
Role: collaborator
Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy
Role: collaborator
Retrospective Analysis of the Epidemiological Change and Determinants of Prognosis of Talaromycosisof Human Immunodeficiency Virus Negative Host in Guangxi
Role: collaborator
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
Role: collaborator
All 8 trials loaded